Phospho-LATS1/2 (Ser909/Ser872) Antibody - #AF8163

>>赠JD卡 进行中>>
(14)   (11)  
产品: 磷酸化 LATS1/2 (Ser909/Ser872) 抗体
货号: AF8163
描述: Rabbit polyclonal antibody to Phospho-LATS1/2 (Ser909/Ser872)
应用: WB IHC
文献验证: WB
反应: Human, Mouse, Rat
预测: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Chicken, Xenopus
蛋白号: O95835 | Q9NRM7
RRID: AB_2840225

浏览相似产品>>

   规格 价格 库存
 100ul RMB¥ 2800 现货
 200ul RMB¥ 3800 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:1000-3000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Phospho-LATS1/2 (Ser909/Ser872) Antibody detects endogenous levels of LATS1/2 only when phosphorylated at Ser909/872.
RRID:
AB_2840225
引用格式: Affinity Biosciences Cat# AF8163, RRID:AB_2840225.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

h-warts; Large tumor suppressor homolog 1; LATS large tumor suppressor homolog 1; LATS1; LATS1_HUMAN; Serine threonine protein kinase LATS1; Serine/threonine-protein kinase LATS1; WARTS; WARTS protein kinase; wts; FLJ13161; Kinase phosphorylated during mitosis protein; KPM; Large tumor suppressor homolog 2; Large tumor suppressor homolog 2 Drosophila; Large tumor suppressor kinase 2; LATS large tumor suppressor Drosophila homolog 2; LATS large tumor suppressor homolog 2; Lats2; LATS2_HUMAN; Serine/threonine kinase kpm; Serine/threonine protein kinase kpm; Serine/threonine-protein kinase kpm; Serine/threonine-protein kinase LATS2; Warts like kinase; Warts-like kinase;

抗原和靶标

免疫原:

A synthesized peptide derived from human LATS1/2 around the phosphorylation site of Ser909/872.

基因/基因ID:
LATS1(9113) | LATS2(26524)

研究领域

· Environmental Information Processing > Signal transduction > Hippo signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway - multiple species.   (View pathway)

文献引用

1). Melatonin reverses tumor necrosis factor-alpha-induced metabolic disturbance of human nucleus pulposus cells via MTNR1B/Gαi2/YAP signaling. International Journal of Biological Sciences, 2022 (PubMed: 35342351) [IF=8.2]

Application: WB    Species: human    Sample: NP cells

Figure 5. | YAP mediates melatonin-induced protective effects on NP cells in the presence of TNF-α.(E) WB assay of Hippo/YAP signaling proteins in NP cells following the indicated treatment.
2). Identification of Gαi3 as a promising molecular oncotarget of pancreatic cancer. Cell death & disease, 2024 (PubMed: 39349432) [IF=8.1]
3). USF1-induced upregulation of LINC01048 promotes cell proliferation and apoptosis in cutaneous squamous cell carcinoma by binding to TAF15 to transcriptionally activate YAP1. Cell Death & Disease, 2019 (PubMed: 30931936) [IF=8.1]

Application: WB    Species:    Sample: CSCC cells

Fig. 5| LINC01048 regulated the activity of Hippo pathway in CSCC cells. a 500 mRNAs were selected out due to their highest fold change in response to LINC01048 knockdown. b 500 mRNAs were subjected to KEGG pathway analysis. c The levels of Hippo pathway proteins were tested with western blotting in cells transfected with sh-LINC01048#2 or sh-NC
4). Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling. PHYTOMEDICINE, 2020 (PubMed: 32771890) [IF=6.7]

Application: WB    Species: human    Sample: LX-2 cells

Fig. 6.| PD inhibits liver fibrosis through regulation of Hippo pathway. (A) LX-2 cells were treated with PD (5 μM, 10 μM, 20 μM) for 24 h with or without TGF-β1(5 ng/ml). Western blot analysis of Hippo signaling core factor protein expression.
5). Circular RNA HSDL2 promotes breast cancer progression via miR-7978 ZNF704 axis and regulating hippo signaling pathway. Breast cancer research : BCR, 2024 (PubMed: 38937788) [IF=6.1]

Application: WB    Species: Mouse    Sample:

Fig. 7 (A-C) A lung metastasis model built by tail vein injection of breast cancer cells. In vivo imaging of lung metastatic tumors in mice using fluorescence imaging. (D-G) MDA-MB-231 cells (circHSDL2 group and circ-NC group) were subcutaneously implanted into female nude mice. The tumor volume and weight in the circHSDL2 group were significantly larger than those in the circ-NC group. (H) Representative Datas of immunohistochemistry for ZNF704, MST2 and TAZ in the two groups. (I) Proteins in the tumor tissues of both groups detected by Western blotting for ZNF704 and the relevant proteins in the Hippo pathway. Data were reported as mean ± SD from at least three tests *p 
6). Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP. Cells, 2019 (PubMed: 30999669) [IF=6.0]
7). Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway. Molecular Therapy-Oncolytics, 2020 (PubMed: 32055676) [IF=5.3]

Application: WB    Species: human    Sample: FTC cells

Figure 4.| Upregulation of ST6GAL2 Rescues Tumorigenesis of FTC238 Cells and Resuppresses Hippo Signaling Pathway Activity(A–F) ST6GAL2 knockdown cells were transfected with ST6GAL2 overexpression vectors, and the proliferation,migration, and invasion capacities of FTC cells were enhanced. (G and H) Western blotting was performed to determine the levels of Hippo signaling molecules in FTC cells. *p < 0.05; scale bars, 20 mm.
8). A derivant of ginsenoside CK and its inhibitory effect on hepatocellular carcinoma. LIFE SCIENCES, 2022 (PubMed: 35690105) [IF=5.2]
9). Ischemia-inhibited ferric chelate reductase 1 improves ferroptosis-mediated intestinal ischemia injury via Hippo signaling. International immunopharmacology, 2024 (PubMed: 38531200) [IF=4.8]
10). Anti-cancer effects of nitazoxanide in epithelial ovarian cancer in-vitro and in-vivo. Chemico-biological interactions, 2024 (PubMed: 39084502) [IF=4.7]
加载更多

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.